Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
September 2013, Vol 4, No 7
September 2013, Vol 4, No 7
New Technologies Bring No Upward Shift in Treatment of Local Prostate Cancer
By
Wayne Kuznar
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
September 2013, Vol 4, No 7
Chicago, IL—The rate of therapy for localized prostate cancer does not increase in markets with higher penetration of robotic surgical technology and intensity-modulated radiation therapy (IMRT), according to an examination of trends using the Surveillance, Epidemiology and End Results (SEER)-Medicare–linked database, according to a poster presentation at the 2013 American Society of Clinical Oncology meeting by lead investigator Florian Rudolf Schroeck, MD, MS, Clinical Lecturer, Urology, University of Michigan, Ann Arbor.
Read Article
BRCA Mutation a Robust Biomarker for Olaparib Benefit in Patients with Ovarian Cancer
By
Alice Goodman
Personalized Medicine
September 2013, Vol 4, No 7
Chicago, IL—Olaparib maintenance therapy prolonged progression-free survival (PFS) and the time to disease progression after a second subsequent therapy in patients with platinum-sensitive relapsed serous ovarian cancer. This effect was particularly robust in patients with a BRCA mutation, based on an updated analysis of Study 19.
Read Article
Ponatinib Given Early May Suppress New Mutations in Patients with CML
By
Alice Goodman
Personalized Medicine
September 2013, Vol 4, No 7
Chicago, IL—A new analysis of mutations at baseline and at the end of treatment provides information about the response to ponatinib (Iclusig) in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphocytic leukemia (ALL) enrolled in the phase 2 PACE study. The results were presented at the 2013 annual meeting of the American Society of Clinical Oncology.
Read Article
Lymphedema a Common Problem in Head and Neck Cancer
By
Alice Goodman
Head and Neck Cancer
September 2013, Vol 4, No 7
Berlin, Germany—Although little is known about the prevalence of lymphedema in patients with head and neck cancer, a series of studies showed that 75% of patients with head and neck cancer have problematic lymphedema internally and externally.
Read Article
Bracing for Change in Healthcare Coverage with Medicaid Expansion: What This Means for Cancer Care Delivery
By
Caroline Helwick
September 2013, Vol 4, No 7
Hollywood, FL—As part of the Affordable Care Act (ACA), Medicaid expansion necessitates that states soon come to grips with massive change in healthcare coverage. Matthew E. Brow, Vice President, Public Policy and Reimbursement Strategy, McKesson Specialty Health and the US Oncology Network, updated attendees at the Third Annual Conference of the Association for Value-Based Cancer Care on progress in this area.
Read Article
Defining the Role of Government in Future Oncology Care
By
Caroline Helwick
September 2013, Vol 4, No 7
Hollywood, FL—Regardless of one’s personal opinion of the role of government in healthcare, the Affordable Care Act (ACA) will be implemented, which means government will be playing a more significant role, as 2 speakers pointed out at the Third Annual Conference of the Association for Value-Based Cancer Care.
Read Article
NCCN/National Business Group on Health Collaboration Produces Guide for Employers
By
Caroline Helwick
September 2013, Vol 4, No 7
>Hollywood, FL—A collaboration between the National Comprehensive Cancer Network (NCCN) and the National Business Group on Health can help employers navigate the confusing landscape of employee benefits.
Read Article
Abraxane Receives New Indication for Metastatic Pancreatic Cancer
FDA Approvals, News & Updates
September 2013, Vol 4, No 7
The US Food and Drug Administration (FDA) approved a new indication for paclitaxel protein-bound particles for injectable suspension, albumin-bound (Abraxane; Celgene) for the treatment of patients with metastatic pancreatic cancer.
Read Article
Ibrutinib Shows Durable Remissions in Patients with Relapsed CLL
In the Literature
September 2013, Vol 4, No 7
Treatment for chronic lymphocytic leukemia (CLL) has resulted in few cases of durable remissions. Bruton’s tyrosine kinase (BTK), an essential component of B-cell receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.
Read Article
Industry-Funded Studies Receive Greater Prominence at ASCO Meetings
In the Literature
September 2013, Vol 4, No 7
>The American Society of Clinical Oncology (ASCO) revised its policy on financial conflicts of interest (FCOIs) in 2005, establishing for the first time certain types of financial relationships for clinical trial principal investigators.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma